Come up with a name for your new list and we'll add to it:
Qu Biologics raised a round of funding on April 06, 2016. Investors include
Genome British Columbia.
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an immune response in…